SCHEMBL6771056

SCHEMBL6771056

NNC(=O)C1CCCc2c1c1cc(OCCc3ccccc3)ccc1n2Cc1ccccc1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 7/20 0.44
HTR6 P50406 2/20 0.43
EGFR P00533 3/20 0.41
IGF1R P08069 3/20 0.41
FLT4 P35916 3/20 0.41
KDR P35968 3/20 0.41
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771051 1.00 PLA2G2A (0.44) PLA2G2AHTR6EGFRIGF1RFLT4
SCHEMBL6776197 0.91 PLA2G2A (0.46) PLA2G2AHTR6EGFRIGF1RFLT4
SCHEMBL6699386 0.79 HTR6 (0.67) PLA2G2AHTR6
SCHEMBL6776017 0.77 PLA2G2A (0.48) PLA2G2AEGFRIGF1RFLT4KDR
SCHEMBL818539 0.73 PLA2G2A (0.59) PLA2G2AHTR6
SCHEMBL29862561 0.73 PLA2G2A (0.59) PLA2G2AHTR6
SCHEMBL6771316 0.73 PLA2G2A (0.49) PLA2G2AEGFRIGF1RFLT4KDR
SCHEMBL11838754 0.72 HTR6 (0.56) PLA2G2AHTR6
SCHEMBL11826084 0.72 HTR6 (0.66) PLA2G2AHTR6
SCHEMBL11826395 0.71 HTR6 (0.53) PLA2G2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
EP-0839806-B1 Substituted tricyclics LILLY CO ELI (US) 2003-07-09 EP disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed
EP-0839806-A1 Substituted tricyclics ELI LILLY AND COMPANY (US) 1998-05-06 EP disclosed